Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Egyesült Államok
133 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Where
- Chapel Hill, Cleveland, Columbus, Dallas, Denver, Nashville, Portland, Sarasota, Seattle
- Életkor
- 18 év and over
- People
- 60
- Run by
- Accutar Biotechnology Inc
See details and how to joinNCT05780034 - 1. fázisTaking peopleA Study of NX-1607 in Adults With Advanced Malignancies
- Where
- Aurora, Chapel Hill, Charlottesville, Chicago, Duarte, Houston, Los Angeles, Oklahoma City, San Francisco, Seattle
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05107674 - 1/2. fázisBefejeződöttA Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
- Where
- Atlanta, Louisville, New York
- Életkor
- 18 év and over
- People
- 32 worldwide
- Run by
- Ranok Therapeutics (Hangzhou) Co., Ltd.
See details and how to joinNCT05487170 - 2. fázisTaking peopleLocal Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- Where
- Pittsburgh
- Életkor
- 18 év to 79 év
- People
- 30
- Run by
- John Lister
See details and how to joinNCT05281809 - 2. fázisTaking peopleEpcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Where
- Chapel Hill, Hackensack, New York, Rochester, Salt Lake City, St Louis
- Életkor
- 18 év and over
- People
- 120
- Run by
- Academic and Community Cancer Research United
See details and how to joinNCT06238648 - No phaseTaking peopleOptimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Where
- Palo Alto
- Életkor
- 18 év and over
- People
- 300
- Run by
- Adaptive Biotechnologies
See details and how to joinNCT05255354 - 2. fázisTaking peopleDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Where
- Atlanta, Boca Raton, Canton, Fountain Valley, Greenville, Hollywood, Indianapolis, New Orleans, Omaha, Pittsburgh, Plantation, Santa Fe, St. Petersburg, Toledo, Watertown, West Reading
- Életkor
- 18 év and over
- People
- 102 worldwide
- Run by
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617 - 1/2. fázisTaking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Cincinnati, Columbus, Dallas, Goshen
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394